ReviewVirchows Archiv : an international journal of pathology2014
Molecular tests as prognostic factors in breast cancer.
Review in Virchows Archiv : an international journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Review
- The Preoperative Serum Levels of the Anaphylatoxins C3a and C5a and Their Association with Clinico-Pathological Factors in Breast Cancer Patients.Archives of Razi Institute · 2022Article
- The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women.Scientific reports · 2020Article
- Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer.PloS one · 2019Article
- Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.BMC cancer · 2018Article
- Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.Breast cancer research and treatment · 2018Article
- A lectin-based approach to detecting carcinogenesis in breast tissue.Oncology letters · 2016Article
- The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.Biomarker research · 2016Article
- Novel Molecular Markers for Breast Cancer.Biomarkers in cancer · 2016Review
- The 82-plex plasma protein signature that predicts increasing inflammation.Scientific reports · 2015Article
- The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.BMC medicine · 2015Review
- [Molecular pathology for breast cancer: Importance of the gene expression profile].Der Pathologe · 2015Review
- Tumour location within the breast: Does tumour site have prognostic ability?Ecancermedicalscience · 2015Article
- Molecular classification of breast cancer.Virchows Archiv : an international journal of pathology · 2014Article
- Prognostic biomarkers: an introduction.Virchows Archiv : an international journal of pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In early breast cancer, prognostic tests are used to guide decisions on adjuvant systemic hormonal therapy, chemotherapy and targeted therapy treatment. This has led to large research efforts to identify novel prognostic markers in breast cancer. At present, the tissue factors used to guide treatment of breast cancer patients are tumor size, lymph node status, histologic grade, ER status, PR status, and HER2 status; in addition, multigene-expression-based prognostic tests are rapidly emerging. While identification of prognostic gene expression profiles has been successful, it has not been possible yet to identify robust clinically useful predictors of response to systemic treatment. As a result of rapid advances in technology and bioinformatics, it has become possible to analyze large series of breast carcinomas using high-throughput genetic techniques, including whole genome sequence analysis and gene expression profiling. These genomic studies will lead to the development of additional prognostic and predictive tissue-based tests. The most important aspects of the currently used tissue-based prognostic and predictive tests and the research in this area are reviewed.
Indexed as
Identifiers
24487789What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.